| Rx0000095 |
Salix Pharmaceuticals, Inc. |
04/22/2025 |
65649055102 |
RELISTOR® (methylnaltrexone bromide) 12mg/0.6mL, vial |
01/01/2025 |
9.62 |
169.93 |
12/31/2030 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
04/22/2025 |
65649055103 |
RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, 7ct |
01/01/2025 |
67.33 |
1189.50 |
12/31/2030 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
04/22/2025 |
65649055107 |
RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, vial |
01/01/2025 |
9.62 |
169.93 |
12/31/2030 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
04/22/2025 |
65649055204 |
RELISTOR® (methylnaltrexone bromide) PFS 8 mg/0.4mL, 7ct |
01/01/2025 |
67.33 |
1189.50 |
12/31/2030 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
04/22/2025 |
65649030103 |
XIFAXAN® (rifaximin) 200 mg Tablets, 30 ct |
01/01/2025 |
19.07 |
336.78 |
07/24/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
04/22/2025 |
65649030303 |
XIFAXAN® (rifaximin) 550mg Tablets HUD 6 cards of 10, 60ct Card |
01/01/2025 |
196.03 |
3463.26 |
10/02/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
04/22/2025 |
65649030302 |
XIFAXAN® (rifaximin) 550mg Tablets, 60ct |
01/01/2025 |
196.03 |
3463.26 |
10/02/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000011 |
Sanofi |
04/30/2025 |
00024591902 |
DUPIXENT® (dupilumab) injection200 mg/1.14 mL (1.14 mL/pen) - 2 pens |
01/03/2025 |
190.16 |
3993.36 |
03/28/2031 |
Single Source Drug |
None |
None |
None |
1 |
Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation.
Our US prescription medicine pricing principles focus on three key areas:
clear rationale for pricing at the time of launch of a new medicine;
reporting of pricing actions for our medicines in the United States over time; and
continued transparency around our pricing decisions.
You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
04/30/2025 |
00024591801 |
DUPIXENT® (dupilumab) injection200 mg/1.14 mL (1.14 mL/syringe) - 2 syringes |
01/03/2025 |
190.16 |
3993.36 |
03/28/2031 |
Single Source Drug |
None |
None |
None |
1 |
Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation.
Our US prescription medicine pricing principles focus on three key areas:
clear rationale for pricing at the time of launch of a new medicine;
reporting of pricing actions for our medicines in the United States over time; and
continued transparency around our pricing decisions.
You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
04/30/2025 |
00024591502 |
DUPIXENT® (dupilumab) injection300 mg/2 mL (2 mL/pen) - 2 pens |
01/03/2025 |
190.16 |
3993.36 |
03/28/2031 |
Single Source Drug |
None |
None |
None |
1 |
Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation.
Our US prescription medicine pricing principles focus on three key areas:
clear rationale for pricing at the time of launch of a new medicine;
reporting of pricing actions for our medicines in the United States over time; and
continued transparency around our pricing decisions.
You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
04/30/2025 |
00024591401 |
DUPIXENT® (dupilumab) injection300 mg/2 mL (2 mL/syringe) - 2 syringes |
01/03/2025 |
190.16 |
3993.36 |
03/28/2031 |
Single Source Drug |
None |
None |
None |
1 |
Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation.
Our US prescription medicine pricing principles focus on three key areas:
clear rationale for pricing at the time of launch of a new medicine;
reporting of pricing actions for our medicines in the United States over time; and
continued transparency around our pricing decisions.
You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
04/30/2025 |
00024590801 |
KEVZARA® (sarilumab) injection 150 mg/1.14 mL (1.14 mL syringe) - 2 syringes |
01/03/2025 |
260.59 |
4603.71 |
09/19/2031 |
Single Source Drug |
None |
None |
None |
1 |
Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation.
Our US prescription medicine pricing principles focus on three key areas:
clear rationale for pricing at the time of launch of a new medicine;
reporting of pricing actions for our medicines in the United States over time; and
continued transparency around our pricing decisions.
You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
04/30/2025 |
00024592001 |
KEVZARA® (sarilumab) injection 150 mg/1.14 mL (1.14 mL/pen) - 2 pens |
01/03/2025 |
260.59 |
4603.71 |
09/19/2031 |
Single Source Drug |
None |
None |
None |
1 |
Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation.
Our US prescription medicine pricing principles focus on three key areas:
clear rationale for pricing at the time of launch of a new medicine;
reporting of pricing actions for our medicines in the United States over time; and
continued transparency around our pricing decisions.
You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
04/30/2025 |
00024592201 |
KEVZARA® (sarilumab) injection 200 mg/1.14 mL (1.14 mL/pen) - 2 pens |
01/03/2025 |
260.59 |
4603.71 |
09/19/2031 |
Single Source Drug |
None |
None |
None |
1 |
Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation.
Our US prescription medicine pricing principles focus on three key areas:
clear rationale for pricing at the time of launch of a new medicine;
reporting of pricing actions for our medicines in the United States over time; and
continued transparency around our pricing decisions.
You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
04/30/2025 |
00024591001 |
KEVZARA® (sarilumab) injection 200 mg/1.14 mL (1.14 mL/syringe) - 2 syringes |
01/03/2025 |
260.59 |
4603.71 |
09/19/2031 |
Single Source Drug |
None |
None |
None |
1 |
Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation.
Our US prescription medicine pricing principles focus on three key areas:
clear rationale for pricing at the time of launch of a new medicine;
reporting of pricing actions for our medicines in the United States over time; and
continued transparency around our pricing decisions.
You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
04/30/2025 |
00024065401 |
SARCLISA® (isatuximab-irfc) injection100 mg/5 mL (20 mg/mL) (5 mL/vial) - 1 vial |
01/03/2025 |
51.45 |
842.94 |
10/19/2032 |
Single Source Drug |
None |
None |
None |
1 |
Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation.
Our US prescription medicine pricing principles focus on three key areas:
clear rationale for pricing at the time of launch of a new medicine;
reporting of pricing actions for our medicines in the United States over time; and
continued transparency around our pricing decisions.
You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
04/30/2025 |
00024065601 |
SARCLISA® (isatuximab-irfc) injection500 mg/25 mL (20 mg/mL) (25 mL/vial) - 1 vial |
01/03/2025 |
257.24 |
4214.72 |
10/19/2032 |
Single Source Drug |
None |
None |
None |
1 |
Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation.
Our US prescription medicine pricing principles focus on three key areas:
clear rationale for pricing at the time of launch of a new medicine;
reporting of pricing actions for our medicines in the United States over time; and
continued transparency around our pricing decisions.
You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
04/30/2025 |
49281075221 |
TUBERSOL®(Tuberculin tests) 5 tub. unit/0.1 mL, 1VIAL (ML) |
01/01/2025 |
9.10 |
110.23 |
None |
Single Source Drug |
None |
None |
None |
1 |
Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation.
Our US prescription medicine pricing principles focus on three key areas:
clear rationale for pricing at the time of launch of a new medicine;
reporting of pricing actions for our medicines in the United States over time; and
continued transparency around our pricing decisions.
You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
04/30/2025 |
49281075222 |
TUBERSOL®(Tuberculin tests) 5 tub. unit/0.1 mL, 5 VIAL (ML) |
01/01/2025 |
35.46 |
429.50 |
None |
Single Source Drug |
None |
None |
None |
1 |
Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation.
Our US prescription medicine pricing principles focus on three key areas:
clear rationale for pricing at the time of launch of a new medicine;
reporting of pricing actions for our medicines in the United States over time; and
continued transparency around our pricing decisions.
You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
04/30/2025 |
49281079051 |
Typhim Vi® (Typhoid vaccine) 0.5 mL (1-dose) syringe |
01/01/2025 |
6.98 |
146.57 |
None |
Single Source Drug |
None |
None |
None |
1 |
Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation.
Our US prescription medicine pricing principles focus on three key areas:
clear rationale for pricing at the time of launch of a new medicine;
reporting of pricing actions for our medicines in the United States over time; and
continued transparency around our pricing decisions.
You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
04/30/2025 |
49281079020 |
Typhim Vi® (Typhoid vaccine) 10 mL (0.5 mL dose) vial |
01/01/2025 |
96.49 |
2026.30 |
None |
Single Source Drug |
None |
None |
None |
1 |
Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation.
Our US prescription medicine pricing principles focus on three key areas:
clear rationale for pricing at the time of launch of a new medicine;
reporting of pricing actions for our medicines in the United States over time; and
continued transparency around our pricing decisions.
You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000011 |
Sanofi |
04/30/2025 |
49281091501 |
YF-VAX (yellow fever vaccine live/PF) 10 exp4.74 unit/0.5 mL, 1 VIAL (EA) |
01/01/2025 |
92.46 |
1119.83 |
None |
Single Source Drug |
None |
None |
None |
1 |
Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation.
Our US prescription medicine pricing principles focus on three key areas:
clear rationale for pricing at the time of launch of a new medicine;
reporting of pricing actions for our medicines in the United States over time; and
continued transparency around our pricing decisions.
You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000028 |
Servier Pharmaceuticals LLC |
04/30/2025 |
72694095401 |
ONCASPAR INJECTION 1 VIAL 5 ML 3750 IU |
01/01/2025 |
1276.91 |
26815.15 |
None |
Single Source Drug |
None |
None |
None |
1 |
Servier's pricing strategy is the result of a comprehensive assessment of various factors, including competitive market dynamics, escalating supply chain and operational expenses, distribution and wholesaler fees, as well as research and development investments. The pricing of products also accounts for the unique challenges posed by small patient populations. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000004 |
Shionogi Inc. |
04/30/2025 |
59630026610 |
FETROJA, for injection, 1 gram of cefiderocol, 2 grams of FETROJA for injection every 8 hours, 10 single-dose vials per pack |
01/01/2025 |
131.80 |
2328.40 |
09/03/2035 |
Single Source Drug |
None |
None |
None |
1 |
Pricing decisions are made based on careful consideration of many factors including, but not limited to, therapeutic area, business costs, research and development costs, and market dynamics. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000074 |
Sigmapharm Laboratories, LLC |
01/29/2025 |
42794002808 |
Disulfiram 250mg tablet 30ct bottle |
03/29/2025 |
98.50 |
170.00 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000175 |
Sobi Inc |
04/16/2025 |
66658023407 |
Kineret Subcutaneous Solution Prefilled Syringe 100 MG/0.67ML - 7 prefilled syringes |
01/01/2025 |
96.48 |
1474.79 |
07/20/2026 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Inner NDC's for Kineret: 66658023401 |
| Rx0000245 |
Solco Healthcare US, LLC |
05/12/2025 |
43547060210 |
PKGS LISDEX CAPSULES 10MG C2 100 CT |
05/19/2025 |
126.14 |
200.00 |
None |
Non-innovator Multiple Source Drug |
None |
None |
1733790 |
None |
Due to current limited product availability in the market, some customers are willing to pay a higher price (higher than old WAC) to secure additional supply. |
None |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The recommended dosage is 1 capsule per day. So the new WAC cost for a 30-day treatment is $60.00 |
| Rx0000245 |
Solco Healthcare US, LLC |
05/12/2025 |
43547060310 |
PKGS LISDEX CAPSULES 20MG C2 100 CT |
05/19/2025 |
126.14 |
200.00 |
None |
Non-innovator Multiple Source Drug |
None |
None |
1976629 |
None |
Due to current limited product availability in the market, some customers are willing to pay a higher price (higher than old WAC) to secure additional supply. |
None |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The recommended dosage is 1 capsule per day. So the new WAC cost for a 30-day treatment is $60.00 |
| Rx0000245 |
Solco Healthcare US, LLC |
05/12/2025 |
43547060410 |
PKGS LISDEX CAPSULES 30MG C2 100 CT |
05/19/2025 |
126.14 |
200.00 |
None |
Non-innovator Multiple Source Drug |
None |
None |
5286437 |
None |
Due to current limited product availability in the market, some customers are willing to pay a higher price (higher than old WAC) to secure additional supply. |
None |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The recommended dosage is 1 capsule per day. So the new WAC cost for a 30-day treatment is $60.00 |
| Rx0000245 |
Solco Healthcare US, LLC |
05/12/2025 |
43547060510 |
PKGS LISDEX CAPSULES 40MG C2 100 CT |
05/19/2025 |
126.14 |
200.00 |
None |
Non-innovator Multiple Source Drug |
None |
None |
3597728 |
None |
Due to current limited product availability in the market, some customers are willing to pay a higher price (higher than old WAC) to secure additional supply. |
None |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The recommended dosage is 1 capsule per day. So the new WAC cost for a 30-day treatment is $60.00 |
| Rx0000245 |
Solco Healthcare US, LLC |
05/12/2025 |
43547060610 |
PKGS LISDEX CAPSULES 50MG C2 100 CT |
05/19/2025 |
126.14 |
200.00 |
None |
Non-innovator Multiple Source Drug |
None |
None |
1747303 |
None |
Due to current limited product availability in the market, some customers are willing to pay a higher price (higher than old WAC) to secure additional supply. |
None |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The recommended dosage is 1 capsule per day. So the new WAC cost for a 30-day treatment is $60.00 |
| Rx0000245 |
Solco Healthcare US, LLC |
05/12/2025 |
43547060710 |
PKGS LISDEX CAPSULES 60MG C2 100 CT |
05/19/2025 |
126.14 |
200.00 |
None |
Non-innovator Multiple Source Drug |
None |
None |
0 |
1 |
Due to current limited product availability in the market, some customers are willing to pay a higher price (higher than old WAC) to secure additional supply. |
None |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The recommended dosage is 1 capsule per day. So the new WAC cost for a 30-day treatment is $60.00 |
| Rx0000245 |
Solco Healthcare US, LLC |
05/12/2025 |
43547060810 |
PKGS LISDEX CAPSULES 70MG C2 100 CT |
05/19/2025 |
116.00 |
200.00 |
None |
Non-innovator Multiple Source Drug |
None |
None |
0 |
1 |
Due to current limited product availability in the market, some customers are willing to pay a higher price (higher than old WAC) to secure additional supply. |
None |
No change or improvement to the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The recommended dosage is 1 capsule per day. So the new WAC cost for a 30-day treatment is $60.00 |
| Rx0000575 |
Stallergenes Greer USA |
04/09/2025 |
22840010730 |
PALFORZIA 120MG, (15) 20mg capsules and (15) 100mg capsules |
03/03/2025 |
319.88 |
959.64 |
12/31/2025 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age.
2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx.
3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers.
4. Significant cost increases to the REMS program that is required for this drug.
5. Significant cost increases to the manufacturing and packaging of the product.
6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy. |
None |
There was no change/improvement to this NDC. |
None |
09/04/2023 |
Nestle Health Science |
None |
1 |
Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia. |
584.26 |
533.57 |
2020 |
445.00 |
None |
None |
| Rx0000575 |
Stallergenes Greer USA |
04/09/2025 |
22840010345 |
PALFORZIA 12MG, (30) 1mg capsules and (15) 10 mg capsules |
03/03/2025 |
319.88 |
959.64 |
12/31/2025 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age.
2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx.
3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers.
4. Significant cost increases to the REMS program that is required for this drug.
5. Significant cost increases to the manufacturing and packaging of the product.
6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy. |
None |
There was no change/improvement to this NDC. |
None |
09/04/2023 |
Nestle Health Science |
None |
1 |
Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia. |
584.26 |
533.57 |
2020 |
445.00 |
None |
None |
| Rx0000575 |
Stallergenes Greer USA |
04/09/2025 |
22840010860 |
PALFORZIA 160MG, (45) 20mg capsules and (15) 100mg capsules |
03/03/2025 |
319.88 |
959.64 |
12/31/2025 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age.
2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx.
3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers.
4. Significant cost increases to the REMS program that is required for this drug.
5. Significant cost increases to the manufacturing and packaging of the product.
6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy. |
None |
There was no change/improvement to this NDC. |
None |
09/04/2023 |
Nestle Health Science |
None |
1 |
Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia. |
584.26 |
533.57 |
2020 |
445.00 |
None |
None |
| Rx0000575 |
Stallergenes Greer USA |
04/09/2025 |
22840010930 |
PALFORZIA 200MG, (30) 100mg capsules |
03/03/2025 |
319.88 |
959.64 |
12/31/2025 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age.
2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx.
3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers.
4. Significant cost increases to the REMS program that is required for this drug.
5. Significant cost increases to the manufacturing and packaging of the product.
6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy. |
None |
There was no change/improvement to this NDC. |
None |
09/04/2023 |
Nestle Health Science |
None |
1 |
Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia. |
584.26 |
533.57 |
2020 |
445.00 |
None |
None |
| Rx0000575 |
Stallergenes Greer USA |
04/09/2025 |
22840010415 |
PALFORZIA 20MG, (15) 20mg capsules |
03/03/2025 |
319.88 |
959.64 |
12/31/2025 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age.
2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx.
3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers.
4. Significant cost increases to the REMS program that is required for this drug.
5. Significant cost increases to the manufacturing and packaging of the product.
6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy. |
None |
There was no change/improvement to this NDC. |
None |
09/04/2023 |
Nestle Health Science |
None |
1 |
Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia. |
584.26 |
533.57 |
2020 |
445.00 |
None |
None |
| Rx0000575 |
Stallergenes Greer USA |
04/09/2025 |
22840011060 |
PALFORZIA 240MG, (30) 20mg capsules and (30) 100mg capsules |
03/03/2025 |
319.88 |
959.64 |
12/31/2025 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age.
2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx.
3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers.
4. Significant cost increases to the REMS program that is required for this drug.
5. Significant cost increases to the manufacturing and packaging of the product.
6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy. |
None |
There was no change/improvement to this NDC. |
None |
09/04/2023 |
Nestle Health Science |
None |
1 |
Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia. |
584.26 |
533.57 |
2020 |
445.00 |
None |
None |
| Rx0000575 |
Stallergenes Greer USA |
04/09/2025 |
22840011115 |
PALFORZIA 300MG 15/Count |
03/03/2025 |
319.88 |
959.64 |
12/31/2025 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age.
2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx.
3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers.
4. Significant cost increases to the REMS program that is required for this drug.
5. Significant cost increases to the manufacturing and packaging of the product.
6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy. |
None |
There was no change/improvement to this NDC. |
None |
09/04/2023 |
Nestle Health Science |
None |
1 |
Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia. |
584.26 |
533.57 |
2020 |
445.00 |
None |
None |
| Rx0000575 |
Stallergenes Greer USA |
04/09/2025 |
22840011130 |
PALFORZIA 300MG 30/Count |
03/03/2025 |
639.75 |
1919.28 |
12/31/2025 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age.
2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx.
3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers.
4. Significant cost increases to the REMS program that is required for this drug.
5. Significant cost increases to the manufacturing and packaging of the product.
6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy. |
None |
There was no change/improvement to this NDC. |
None |
09/04/2023 |
Nestle Health Science |
None |
1 |
Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia. |
1168.42 |
1067.14 |
2020 |
890.00 |
None |
None |
| Rx0000575 |
Stallergenes Greer USA |
04/09/2025 |
22840012745 |
PALFORZIA 3MG, (45) 1 mg capsules in one blister pack |
03/03/2025 |
319.88 |
959.64 |
12/31/2025 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age.
2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx.
3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers.
4. Significant cost increases to the REMS program that is required for this drug.
5. Significant cost increases to the manufacturing and packaging of the product.
6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy. |
None |
There was no change/improvement to this NDC. |
None |
09/04/2023 |
Nestle Health Science |
None |
1 |
Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia. |
584.26 |
533.57 |
2020 |
445.00 |
None |
None |
| Rx0000575 |
Stallergenes Greer USA |
04/09/2025 |
22840010530 |
PALFORZIA 40MG (30), 20mg capsules |
03/03/2025 |
319.88 |
959.64 |
12/31/2025 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age.
2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx.
3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers.
4. Significant cost increases to the REMS program that is required for this drug.
5. Significant cost increases to the manufacturing and packaging of the product.
6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy. |
None |
There was no change/improvement to this NDC. |
None |
09/04/2023 |
Nestle Health Science |
None |
1 |
Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia. |
584.26 |
533.57 |
2020 |
445.00 |
None |
None |
| Rx0000575 |
Stallergenes Greer USA |
04/09/2025 |
22840010290 |
PALFORZIA 6MG, (90) 1 mg capsules in one blister pack |
03/03/2025 |
319.88 |
959.64 |
12/31/2025 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age.
2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx.
3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers.
4. Significant cost increases to the REMS program that is required for this drug.
5. Significant cost increases to the manufacturing and packaging of the product.
6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy. |
None |
There was no change/improvement to this NDC. |
None |
09/04/2023 |
Nestle Health Science |
None |
1 |
Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia. |
584.26 |
533.57 |
2020 |
445.00 |
None |
None |
| Rx0000575 |
Stallergenes Greer USA |
04/09/2025 |
22840010660 |
PALFORZIA 80MG, (60) 20mg capsules |
03/03/2025 |
319.88 |
959.64 |
12/31/2025 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age.
2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx.
3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers.
4. Significant cost increases to the REMS program that is required for this drug.
5. Significant cost increases to the manufacturing and packaging of the product.
6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy. |
None |
There was no change/improvement to this NDC. |
None |
09/04/2023 |
Nestle Health Science |
None |
1 |
Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia. |
584.26 |
533.57 |
2020 |
445.00 |
None |
None |
| Rx0000575 |
Stallergenes Greer USA |
04/09/2025 |
22840011313 |
PALFORZIA INITIAL DOSE PACK contains (1) 0.5mg capsule; (1) 1mg capsule; (1) 0.5mg capsule and (1) 1mg capsule; (3) 1mg capsules; (6) 1mg capsules |
03/03/2025 |
916.51 |
959.64 |
12/31/2025 |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age.
2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx.
3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers.
4. Significant cost increases to the REMS program that is required for this drug.
5. Significant cost increases to the manufacturing and packaging of the product.
6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy. |
None |
There was no change/improvement to this NDC. |
None |
09/04/2023 |
Nestle Health Science |
None |
1 |
Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia. |
39.39 |
35.97 |
2020 |
30.00 |
None |
None |
| Rx0000005 |
Sumitomo Pharma America, Inc. |
04/16/2025 |
63402020230 |
Aptiom 200 mg tablet 30 count bottle |
01/01/2025 |
76.24 |
1347.04 |
08/24/2032 |
Single Source Drug |
None |
None |
None |
1 |
SMPA has made the decision to increase the WAC price of the applicable product effective January 1, 2025. This price change is due to increases in the cost of business operations related to the product. |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000005 |
Sumitomo Pharma America, Inc. |
04/16/2025 |
63402020430 |
Aptiom 400 mg tablet 30 count bottle |
01/01/2025 |
76.24 |
1347.04 |
08/24/2032 |
Single Source Drug |
None |
None |
None |
1 |
SMPA has made the decision to increase the WAC price of the applicable product effective January 1, 2025. This price change is due to increases in the cost of business operations related to the product. |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000005 |
Sumitomo Pharma America, Inc. |
04/16/2025 |
63402020660 |
Aptiom 600 mg tablet 60 count bottle |
01/01/2025 |
152.48 |
2694.08 |
08/24/2032 |
Single Source Drug |
None |
None |
None |
1 |
SMPA has made the decision to increase the WAC price of the applicable product effective January 1, 2025. This price change is due to increases in the cost of business operations related to the product. |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000005 |
Sumitomo Pharma America, Inc. |
04/16/2025 |
63402020830 |
Aptiom 800 mg tablet 30 count bottle |
01/01/2025 |
76.24 |
1347.04 |
08/24/2032 |
Single Source Drug |
None |
None |
None |
1 |
SMPA has made the decision to increase the WAC price of the applicable product effective January 1, 2025. This price change is due to increases in the cost of business operations related to the product. |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
04/21/2025 |
17772013130 |
Qelbree Oral Capsule Extended Release 24 Hour 100 MG Package Quantity 1 Bottle of 30 Capsules |
01/01/2025 |
21.37 |
377.49 |
04/02/2035 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
04/21/2025 |
17772013230 |
Qelbree Oral Capsule Extended Release 24 Hour 150 MG Package Quantity 1 Bottle of 30 Capsules |
01/01/2025 |
21.37 |
377.49 |
04/02/2035 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
04/21/2025 |
17772013330 |
Qelbree Oral Capsule Extended Release 24 Hour 200 MG Package Quantity 1 Bottle of 30 Capsules |
01/01/2025 |
21.37 |
377.49 |
04/02/2035 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
04/21/2025 |
17772013360 |
Qelbree Oral Capsule Extended Release 24 Hour 200 MG Package Quantity 1 Bottle of 60 Capsules |
01/01/2025 |
42.74 |
754.98 |
04/02/2035 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |